button bars forest bayes pooled summary circles
benefit
(statisticaly significant) 		benefit (nominaly significant, not statitically demonstrated) NS not significant harm statitically significant NS harm not significant low certainty due to bias
 
deaths (OS)progression or deaths (PFS)RFS/DFS

mML - NA - all population metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - all population

versus Ipilimumab (10 mg/kg)
nivolumab alone vs. Ipilimumab (10 mg/kg) 1 NS--35%
versus placebo
nivolumab alone vs. placebo 1 ---44%
pembrolizumab alone vs. placebo 1 ---43%

mML - NA - PDL1 positive metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - PDL1 positive

versus placebo
pembrolizumab alone vs. placebo 1 ---46%

mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population

versus ipilimumab alone
nivolumab alone vs. ipilimumab alone 1 -37%-43%-
versus ipilimumab followed by nivolumab
nivolumab followed by ipilimumab vs. ipilimumab followed by nivolumab 1 -52%--

mML - L1 - BRAF mutant metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF mutant

versus placebo plus SoC
atezolizumab plus SoC vs. placebo plus SoC 1 NS-22%-

mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild

versus dacarbazine
nivolumab alone vs. dacarbazine 1 -58%-57%-
versus pembrolizumab alone
atezolizumab plus cometinib vs. pembrolizumab alone 1 NSNS-

mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population

versus ipilimumab alone
pembrolizumab (10mg/kg) vs. ipilimumab alone 1 -31%-42%-
pembrolizumab (10mg/kg) 2 weeks vs. ipilimumab alone 1 -37%-42%-
versus Standard of Care (SoC)
nivolumab alone vs. Standard of Care (SoC) 1 NSNS-
pembrolizumab (10mg/kg) vs. Standard of Care (SoC) 1 -26%-50%-
pembrolizumab (2mg/kg) vs. Standard of Care (SoC) 1 NS-43%-

mML - L2 - BRAF mutant metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - BRAF mutant

versus placebo plus SoC
pembrolizumab plus SoC vs. placebo plus SoC 1 NSNS-

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons